Background As the prevalence of metabolic dysfunction-associated steatohepatitis (MASH) continues to rise, drug development has accelerated, with growing interest in therapeutic strategies that harness metabolic hormones. Metabolic hormone-based approaches, particularly those originally developed for obesity and diabetes, have shown potential to mitigate MASH. Notably, the glucagon-like peptide-1 receptor (GLP-1R) agonist sema...

Background Obesity causes a pro-inflammatory environment and is an established risk factor for a variety of autoimmune diseases. However, the association with the subsequent risk of myasthenia gravis (MG) was unclear. Methods This nationwide cohort study evaluated 3,937,214 adults over 20 years old, using data from the Korean National Health Insurance Service. Participants were categorized by body mass index (BMI) into underwe...